Verve is focused on discovering and developing medicines that safely edit the adult genome and mimic naturally protective gene variants to treat coronary heart disease, the leading cause of death worldwide.
Verve brings together two of the biggest breakthroughs in 21st century biomedicine — human genetic analysis and gene editing — to realize a new future, one of longevity and vitality for tens of millions of people around the globe with or at risk for cardiovascular disease.
Verve has been purpose-built for the task ahead, with a founding team of world-leading experts in cardiovascular medicine, human genetics, gene editing delivery technology and safety, and drug development.
Board of Directors
Collaborations and Licensing
Verve has assembled a portfolio of gene editing and delivery technologies through strategic collaborations and licensing agreements with industry leaders, including Beam Therapeutics, the Broad Institute and Harvard University.